Galapagos/€GLPG
05:30
09:10
12:45
16:25
20:00
1D1W1MYTD1Y5YMAX
About Galapagos
Galapagos NV, abbreviated as GLPG on stock exchanges, is a global biotechnology firm specializing in the discovery and development of small molecule medicines. The company focuses on innovating treatments primarily in the fields of immunology and oncology. Founded in 1999, Galapagos operates out of its headquarters in Belgium and extends its reach across Europe and the United States, aiming to provide transformative therapies for significant unmet medical needs.
Ticker
€GLPG
Sector
Primary listing
AEX
Employees
558
Headquarters
Website
Galapagos Metrics
BasicAdvanced
€1.8B
-
-€4.31
0.03
-
Price and volume
Market cap
€1.8B
Beta
0.03
52-week high
€31.08
52-week low
€20.00
Average daily volume
29K
Financial strength
Current ratio
8.079
Quick ratio
7.89
Long term debt to equity
0.229
Total debt to equity
0.395
Interest coverage (TTM)
-363.88%
Profitability
EBITDA (TTM)
-298.983
Gross margin (TTM)
39.41%
Net profit margin (TTM)
-103.11%
Operating margin (TTM)
-120.29%
Effective tax rate (TTM)
0.83%
Revenue per employee (TTM)
€490,000
Management effectiveness
Return on assets (TTM)
-5.11%
Return on equity (TTM)
-10.39%
Valuation
Price to revenue (TTM)
6.671
Price to book
0.7
Price to tangible book (TTM)
0.76
Price to free cash flow (TTM)
-6.17
Free cash flow yield (TTM)
-16.21%
Free cash flow per share (TTM)
-4.522
Growth
Revenue change (TTM)
5.43%
Earnings per share change (TTM)
-200.41%
3-year revenue growth (CAGR)
-18.29%
10-year revenue growth (CAGR)
12.90%
3-year earnings per share growth (CAGR)
51.90%
10-year earnings per share growth (CAGR)
9.03%
What the Analysts think about Galapagos
Analyst ratings (Buy, Hold, Sell) for Galapagos stock.
Bulls say / Bears say
As of June 30, 2025, Galapagos held approximately €3.1 billion in cash and financial investments, providing substantial runway to fund pivotal GLPG5101 trials through 2028 (GlobeNewswire)
The U.S. FDA granted RMAT designation to GLPG5101 for relapsed/refractory mantle cell lymphoma on August 6, 2025, which can accelerate development timelines and priority review pathways (Galapagos NV)
GLPG5101 demonstrated a 97% complete response rate, 100% MRD negativity, and 97% 12-month progression-free survival in Cohort 3 of the ATALANTA-1 study presented at ICML 2025, underscoring robust efficacy in relapsed/refractory indolent NHL (MarketScreener)
Galapagos incurred a net decrease in cash and cash equivalents and financial investments of €226.3 million in H1 2025, driven by €91.5 million of operational cash burn and €122.7 million of negative exchange rate and fair value adjustments, highlighting substantial cash outflows and FX exposure (GlobeNewswire)
Executive turnover announced in Q1 2025—founder‐CEO Dr. Paul Stoffels retiring, CFO/COO Thad Huston departing, and a new SpinCo CEO appointed—introduces potential execution and strategic continuity risks during a critical separation phase (Galapagos Q1 2025)
GLPG5101 pivotal development is not planned to start until 2026 with first approval not targeted until 2028, delaying potential revenue generation and extending the period before meaningful commercial returns (Galapagos Q1 2025)
Data summarised monthly by Lightyear AI. Last updated on 29 Aug 2025.
Galapagos Financial Performance
Revenues and expenses
Galapagos Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Galapagos stock?
Galapagos (GLPG) has a market cap of €1.8B as of September 10, 2025.
What is the P/E ratio for Galapagos stock?
The price to earnings (P/E) ratio for Galapagos (GLPG) stock is 0 as of September 10, 2025.
Does Galapagos stock pay dividends?
No, Galapagos (GLPG) stock does not pay dividends to its shareholders as of September 10, 2025.
When is the next Galapagos dividend payment date?
Galapagos (GLPG) stock does not pay dividends to its shareholders.
What is the beta indicator for Galapagos?
Galapagos (GLPG) has a beta rating of 0.03. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.